Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.(b)(4).
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on february 7, 2018.(b)(4).The sample was not returned for evaluation nor were any pictures provided.A retention sample from the same product code/lot number visually inspected, the labels were found to be correct.The distribution center was notified of the issue.At the time of the event, two orders were printed and provided to the associate who was picking at the same time.It is likely that the associate picked and placed the product on the same pallet.This resulted in the associate who was shipping placing the shipping labels on the incorrect cases.To avoid the future occurrences of similar events, a process to physically segregate capiox product lines has been implemented.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|